1. Context {#sec139061}
==========

Metabolic syndrome (MetS) ([@A24723R1]) is a collection of interrelated disorders, namely obesity, dyslipidemia, hyperglycemia, and hypertension. Each MetS component increases the risk of cardiovascular disease (CVD), diabetes, and all-cause mortality. According to a study conducted by Gami et al., the synergistic effects of these disorders increase the risk of further disease and mortality much more than the sum of the risk increases from each component ([@A24723R2]). However, other studies have provided different results ([@A24723R3]-[@A24723R5]). MetS increases total mortality from cardiovascular disease by 1.5 fold and risk for cardiovascular death by 2.5 fold ([@A24723R6]). Moreover, individuals with MetS are five times more likely to develop type 2 diabetes ([@A24723R7]). The main causes of MetS remain to be determined. However, it seems that abdominal obesity and insulin resistance are the key components ([@A24723R6]-[@A24723R8]). The most commonly used definitions for MetS are those provided by the world health organization (WHO), the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III), the international diabetes federation (IDF), and the joint interim societies (JIS), as presented in following sections.

MetS is a common disorder, and given that its predisposing factors including obesity, sedentary lifestyle, and exposure to some environmental factors are escalating in many countries, the incidence of MetS is increasing as well ([@A24723R9]). Therefore, MetS is now an emerging health problem at the public and individual levels. Because programs for primary prevention of non-communicable diseases emphasize appropriate evaluation and management of risk factors, ([@A24723R10]) gathering reliable information about the prevalence of MetS in various populations can be very effective in the planning and use of preventive strategies for such diseases.

The prevalence of MetS is not only influenced by excess weight but also by ethnic predisposition, gender, age, race, cultural and lifestyle habits, and environmental factors; thus, its prevalence has large variations in different societies ([@A24723R11], [@A24723R12]). Grundy reported that between 20% and 30% of the adult population in most countries have MetS ([@A24723R13]). Asians have an ethnic predisposition to MetS ([@A24723R14], [@A24723R15]), and it is of special concern for Middle Eastern populations, which are predicted to experience the greatest global burden of diabetes by 2020 ([@A24723R14]). As a country in this region, Iran is reported to have one of the highest prevalence rates of MetS worldwide ([@A24723R16]). The nationwide prevalence of MetS is reported to be 35.6% based on ATP III criteria ([@A24723R14]). In metropolitan Tehran, 42% of women and 24% of men have MetS, with a total age-standardized prevalence of 33.7% ([@A24723R16]). Iran is a vast country with about 70 million people and different ethnicities including Turkish, Kurdish, Arab, Fars, Turkmen, and Baluch living in different regions of the country. The difference in their cultures, socioeconomic status, lifestyle habits, and environmental factors may cause variation in the prevalence of MetS ([@A24723R17]-[@A24723R23]), so it is very important to have an overall estimation of its prevalence in Iran.

2. Objectives {#sec139062}
=============

This study aimed to systematically review the findings of available studies and to combine them to estimate the overall prevalence of MetS in Iran. The other objective of this study was to explore potential sources of heterogeneity in the study findings.

3. Data Sources {#sec139063}
===============

The English-language medical literature was searched from January, 2000 to December, 2013 in Scopus, ISI Web of Science, and PubMed. Using medical subject headings (MeSH), Emtree, and related keywords, we searched for "metabolic syndrome," "dysmetabolic syndrome," "cardiovascular syndrome," and "insulin resistance syndrome" combined with "prevalence" and "Iran," including all subheadings. The Farsi equivalent of these terms and all probable combinations were used to search in Persian databases (i.e., IranMedex, Magiran, SID, and Irandoc). Moreover, the references of selected citations and non-published national surveys were hand-searched. In addition, when articles had incomplete data, at least three e-mails were sent to corresponding authors.

4. Study Selection {#sec139064}
==================

All types of studies, including local and national surveys that reported the prevalence of MetS and were conducted in Iran were reviewed. However, the final review was limited to studies with random sampling on healthy adults and/or on the general population who were aged 18 years and over. The studies that were conducted on subjects with known health disorders were excluded. In the case of multiple publications from the same population, only the largest study was included. The STROBE (strengthening the reporting of observational studies in epidemiology) statement was used for quality control of the studies ([@A24723R24]). The quality of studies was assessed according to variables related to the study objectives, characteristics of the study population, clearly explained inclusion/exclusion criteria, data collection method, as well as the validity, explicit findings, and appropriate data analysis methods of the studies. Non-qualified studies were excluded. Moreover, duplicated citations were not included.

5. Data Extraction {#sec139066}
==================

After determining the qualified papers, data were extracted according to a standard protocol. To improve accuracy and critical appraisal, data extraction was conducted by two independent researchers, and disputes between researchers were resolved by consensus. The following items were extracted from the studies:

General information: first author's name, study location, study date, publication date, definition used for MetS

Population characteristics: sex groups, mean age, and age range

Methodological information: sampling method, sample size, scope of study (urban, rural, or survey)

Study outcomes: reported prevalence of MetS extracted by sex (men, women, and total), and its 95% confidence interval (CI) concerning the prevalence of MetS components.

5.1. Statistical Analysis {#sec139065}
-------------------------

Prevalences are reported with 95% confidence intervals (CI). A Chi-square-based Q test was used to analyze the heterogeneity of reported prevalences and was regarded to be statistically significant at P \< 0.1. Tau-square (τ2) was estimated (using the restricted likelihood method) as the indicator of heterogeneity. After using the heterogeneity test, we found significant variations between study findings; thus, in order to obtain better results, the random effect model was used to estimate the overall prevalence of MetS in Iran. The findings are described in forest plots (the point estimations and their 95% CI). In the next step, meta-regression was used to check the effects of age and publication date as possible sources of heterogeneity among the study findings. The analyses were conducted with STATA software, version 11.0.

6. Results {#sec139067}
==========

In our primary search, and after removing duplicates, we found 379 relevant articles. After excluding non-eligible studies, we recruited the data of 27 local studies and one national study, which included all provinces of Iran. The details of our study selection method are shown in [Figure 1](#fig26340){ref-type="fig"}. In each selected study, the prevalence of MetS was reported according to different criteria. Among the 28 studies, we found 21 reports given according to ATP III (including 12 based on ATP III ([@A24723R25]) and nine based on modified ATP III ([@A24723R26])), six reports according to IDF ([@A24723R7]), and one report according to the Iranian modified IDF ([@A24723R27]), one report according to the WHO criteria, ([@A24723R28]) and five reports according to the JIS criteria ([@A24723R29]).

![Flow Diagram of the Study Selection Process](ircmj-17-12-24723-i001){#fig26340}

The findings of this systematic review are summarized in [Table 1](#tbl35801){ref-type="table"}. For data analysis, we merged the ATP III and modified ATP III reports. The reports of IDF and Iranian modified IDF ([@A24723R27]) were also merged; the meta-analysis was performed on three groups of reports: ATP III, IDF, and JIS. The only study that had used the WHO criteria for MetS was excluded from the analysis. If an article reported the prevalence of MetS according to both ATP III and modified ATP III, both were used as separate reports in the analysis.

###### The Prevalence (95% CI) of Metabolic Syndrome in Iranian Adults in Population-Based Studies

  Reference                                     Location and Study Type                                                                                                              Study Population                                                 Sampling Method                                  Study Date    Publication Date   Age Range, Y   Mean Age (Mean ± SD)                                  Gender   Urban/Rural   Sample Size                     Criteria                                                                                                        Considerations                                                                                                                                                             Prevalence of MetS (95% CI)
  --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------- ------------------------------------------------ ------------- ------------------ -------------- ----------------------------------------------------- -------- ------------- ------------------------------- --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------
  **Faam et al. (**[@A24723R30]**)**            Tehran (TLGS, phase 3), local study                                                                                                  Healthy adults                                                   Random sampling                                  2005 - 2008   2013               20 - 70        T: 40.7 ± 13.9                                        Both     U             T: 4,665; M: 1,976; F: 2,689    JIS                                                                                                             Participants who had diabetes mellitus (n = 390) or body mass index (BMI) less than 18 kg/m (n = 152) were exclude.Waist circumference cut-off points were not mentioned   T: 31.5 (30.1 - 32.8)
  **Ziaee et al. (**[@A24723R31]**)**           Mindoodar district of Qazvin, local study                                                                                            Healthy adults                                                   Multistage random cluster sampling               2010 - 2011   2013               20 - 78        T: 40.08 ± 10.33; M: 42.31 ± 10.56; F: 38.02 ± 9.69   Both     R             T: 1,107; M: 529; F: 578        JIS                                                                                                             Waist circumference cut-off points were ≥ 94 cm in men or ≥ 80 cm in women                                                                                                 T: 39.3 (36.4 - 42.2)
  **Movahed et al. (**[@A24723R32]**)**         Bushehr Port, (Iranian Multicentral Osteoporosis Study), local study                                                                 Postmenopausal women                                             Randomcluster sampling                           2006          2012               50 - 83        F: 58.78 ± 7.8                                        F        U             T: 382                          ATP III                                                                                                                                                                                                                                                                                    T: 68.32 (63.3 - 72.9)
  **Yousefzadeh et al. (**[@A24723R33]**)**     Kerman,local study                                                                                                                   Healthy adults                                                   Random sampling                                                2012               15 - 75        T: 46.52 ± 14.76                                      Both     U             T: 200; M: 81; F: 119           Modified ATP III                                                                                                                                                                                                                                                                           T: 60 (52.8 - 66.8)
  **Azimi-Nezhad et al. (**[@A24723R34]**)**    Greater Khorasan province, (National Survey on Non-communicable Disease), local study                                                Healthy adults                                                   Multistage random sampling                       2003          2012               35 - 55                                                              Both                   T: 1,194; M: 58; F: 605         Modified ATP III                                                                                                                                                                                                                                                                           T: 42.66 (39.8 - 45.4); M: 30.1 (26.3 - 33.9); F: 55.0 (50.9 - 59.0)
  **Hadaegh et al. (**[@A24723R35]**)**         Tehran (TLGS, phase 1), local study                                                                                                  Subjects free of CVD                                             Random sampling                                  1999 - 2001   2012               40 ≤           T:54 ± 9.8; M: 55.3 ± 10.5; F: 53.0 ± 9.3             Both     U             T: 4,248; M:1,856 F:2,392       JIS                                                                                                             Waist circumference cut-off point was ≥ 94.5 cm for both Iranian men and women                                                                                             T: 51.6 (50 - 53.1); M: 45.7 (43.4 - 47.9); F: 56.2 (54.1 - 58.1)
  **Talaei et al. (**[@A24723R36]**)**          Isfahan, Arak and Najafabad, local study                                                                                             Healthy adults                                                   Multistage random sampling                       2001          2012               ≥ 35           T: 50.7 ± 11.6; M: 51.1 ± 11.9; F: 50.3 ± 11.3        Both     Both          T: 6,323; M: 3,068; F: 3,255    Modified ATP III                                                                                                                                                                                                                                                                           T: 37.1 (35.9 - 38.3); M: 21.5 (20.0 - 23.0); F: 51.7 (49.9 - 53.4)
  **Zarkesh et al. (**[@A24723R37]**)**         Tehran, (TLGS, phase III), local study                                                                                               Healthy adults                                                   Random sampling                                  2006 - 2008   2012               ≥ 19           T: 46.1 ± 16.1                                        Both     U             T: 365; M: 134; F: 231          JIS                                                                                                             Waist circumference cut-off point was \> 89 cm in men and \> 91 cm in women                                                                                                T: 43.8 (38.6 -49)
  **Ghorbani et al. (**[@A24723R38]**)**        Semnan, local study                                                                                                                  Healthy adults                                                   Multistage random sampling                       1384          2012               30 - 70        T: 45.7 ± 10.06; M: 46.6 ± 10.4; F: 45.1 ± 9.8        Both     Both          T: 3,799; M: 1,695; F: 2,104    Modified ATP III; IDF                                                                                                                                                                                                                                                                      T: 28.5 (27.1 - 29.9); M: 17 (15.2 - 18.8); F: 37.8 (35.7 - 39.8). T: 35.8 (34.3-37.3); M: 25.4 (23.3-27.5); F: 44.1 (41.9-46.2)
  **Rezaianzadeh et al. (**[@A24723R39]**)**    Yazd (phase I of Yazd Healthy Heart Program)                                                                                         Healthy adults                                                   Cluster sampling                                 2004 - 2005   2012               20 - 74        T: 48.75 ± 15; M: 48.8 ± 15; F: 48.6 ± 15             Both     U             T: 2,000                        IDF                                                                                                                                                                                                                                                                                        T: 30.16 (0.02); M: 31.6 (0.02); F: 30.2 (0.02)
  **Hosseinpanah et al. (**[@A24723R40]**)**    Ghazvin, Kermanshah, Golestan, and Hormozgan (Iranian PCOS Prevalence Study), multicity study                                        Females                                                          Stratified, multistage cluster sampling          2009 - 2010   2011               18 - 45        T: 36 ± 7.5                                           F        U             T: 423                          JIS                                                                                                             Waist circumference cut-off point was ≥ 91 cm                                                                                                                              T: 18.3 (15.1 - 21.5)
  **Esteghamati et al. (**[@A24723R27]**)**     Tehran, (the Third National Surveillance of Risk Factors of Non-communicable Diseases), local study                                  Individuals with body mass index \< 18.5 kg/m^2^ were excluded   Random Cluster sampling                          2007          2011               25 - 64        T: 43.18 ± 0.3; M:43.4 ± 0.3; F: 43.0 ± 0.3           Both     U             T: 2,660; M: 1,245; F: 1,415    Modified ATP III; Iranian modified IDF (waist circumference cut-off point was ≥ 90 cm for both men and women)   Individuals with self-reported diabetes were excluded                                                                                                                      T: 38.09 (36.23 - 39.9); M: 29.9 (27.3 - 32.5); F: 45.3 (42.6 - 47.9). T: 38.4 (36.5-40.2); M: 39.1 (36.3-41.8); F: 37.8 (35.2-40.3)
  **Sahebari et al. (**[@A24723R41]**)**        Great Khorasan province, local study                                                                                                 Healthy adults                                                                                                                  2011                              T: 45.6 ± 12; M: 44.7 ± 12; F: 44.1 ± 13              Both     Both          T: 500; M: 69; F: 431           ATP III; IDF                                                                                                                                                                                                                                                                               T: 53.8 (49.3 - 58.2); M: 21.7 (12.7 - 33.3); F: 51 (46.2 - 55.8). T: 34.2 (30 - 38.5); M: 29 (18.6 - 41.1); F: 57.8 (52.9 - 62.4)
  **Esmaillzadeh et al. (**[@A24723R42]**)**    Tehran, local study                                                                                                                  Female teachers                                                  Multistage random cluster sampling               2007          2011               40 - 60        T: 49 ± 6                                             F        U             T: 486                          ATP III                                                                                                         Subjects taking antihypertensive, lipid lowering, or antidiabetic medications were excluded                                                                                T: 30 (25.9 - 34.3)
  **Esteghamati et al. (**[@A24723R43]**)**     All 30 provinces of Iran (the Third National Surveillance of Risk Factors of Non-Communicable Diseases ) (SuRFNCD), national study   Healthy adults                                                   Random cluster sampling                          2007          2011               25 - 64        T: 43.59 ± 11.2; M: 43.69±11.6; F: 43.5 ± 10.9        Both     Both          T: 3,045; M: 1,468; F: 1,577    IDF                                                                                                             Waist circumference cut-off point was ≥ 90 cm in both males and females                                                                                                    T: 39.9 (38.1 - 41.6); M: 38.2 (35.7 - 40.7); F: 41.5 (39 - 43.9)
  **Ramezani et al. (**[@A24723R44]**)**        Ghazvin, Kermanshah, Golestan, and Hormozgan, multicity study                                                                        Healthy adults                                                   Multistage random cluster sampling                             2011               18 - 45                                                              F        U             T: 914                          Modified ATP III                                                                                                                                                                                                                                                                           T: 17.5 (15.09 - 20.1)
  **Ghasemi et al. (**[@A24723R45]**)**         Tehran, (TLGS, phase 3), local study                                                                                                 Healthy adults                                                   Multistage, stratified random cluster sampling   2007 - 2008   2010               60 - 90                                                              Both     U             T: 137; M: 89; F: 48            ATP III                                                                                                                                                                                                                                                                                    T: 43.8 (35.3 - 52.5); M: 30.3 (21.03 - 40.99); F: 68.8 (53.6 - 61.3)
  **Delavari et al. (**[@A24723R14]**)**        All 30 provinces in Iran, national study                                                                                             Healthy adults                                                   Multistage Random cluster sampling               2007          2009               25 - 64        T: 41.3 ± 3.81; M: 41.5 ± 2.64; F: 41.2 ± 2.74        Both     Both          T: 2,966 M: 1,431; F: 1,535     ATP III; Modified ATP III                                                                                                                                                                                                                                                                  T: 35.6 (34.1 - 37.1); M: 28.8 (27.0-30.5); F: 42.8 (40.4 - 45.1). T: 42.3 (40.7-43.8); M: 36.3 (34.4-38.1); F: 48.5 (46.2-50.9)
  **Jalali et al. (**[@A24723R46]**)**          Akbar abad Koar Fars near Shiraz, local study                                                                                        Healthy adults                                                   Simple random sampling                           2008          2009               18 - 90        T: 38.7 ± 14.3; M: 40.5 ± 15.9; F: 37.4 ± 13.7        Both     R             T: 1,402; M: 360; F: 1,042      ATP III; Modified ATP III; IDF                                                                                                                                                                                                                                                             T: 25.6 (23.3 - 27.9); M: 29.16 (24.5 - 34.1); F: 24.28 (21.7 - 27.0). T: 29 (26.5 - 31.4). T: 33 (30.4 - 35.4)
  **Delavar et al. (**[@A24723R47]**)**         Babol, local study                                                                                                                   Female adults                                                    Systematic random sampling                                     2009               30 - 50        F: 40.2 ± 0.2                                         F        U             T: 944                          ATP III                                                                                                                                                                                                                                                                                    T: 31 (28.1-33.9)
  **Sharifi et al. (**[@A24723R48]**)**         Zanjan, local study                                                                                                                  Healthy adults                                                   Stratified, multistage random sampling           2002 - 2003   2009               \> 20                                                                Both     U             T: 2,941; M: 1,396; F: 1,545    Modified ATP III                                                                                                                                                                                                                                                                           T: 23.7 (22.1 - 25.2); M: 23.1 (20.8 - 25.2); F: 24.4 (22.2 - 26.5)
  **Sarrafzadegan et al. (**[@A24723R49]**)**   Isfehan, Irak, and Najaf-Abad, local study                                                                                           Healthy adults                                                   Two-stage random cluster sampling                2000 - 2001   2008               ≥ 19                                                                 Both     Both          T: 12,514; M: 6,123; F: 6,391   ATP III                                                                                                                                                                                                                                                                                    T: 23.3 (22.5 - 24.0); M: 10.7 (9.9 - 11.4) F: 35.1 (33.9 - 36.2)
  **Hadaegh et al. (**[@A24723R50]**)**         Tehran, (TLGS, phase 1), local study                                                                                                 Healthy adults                                                   Multistage random cluster sampling               1999 - 2001   2008               ≥ 20           T: 42.6 ± 13.6                                        Both     U             T: 4,568; M: 1,882; F: 2,686    WHO                                                                                                             Diabetes patients were excluded                                                                                                                                            T: 9.2 (8.3 - 10.0)
  **Zabetian et al. (**[@A24723R51]**)**        Tehran, (TLGS, phase 1), local study                                                                                                 Healthy adults                                                   Multistage random cluster sampling               1999 - 2001   2007               ≥ 20           T: 42.7 ± 15.0 ; M: 44.1 ± 15.6; F: 41.7 ± 14.4       Both     U             T: 10,368 M: 4,397; F: 5,971    IDF                                                                                                                                                                                                                                                                                        T: 31 (30.1 - 31.8); M: 21 (19.7 - 22.2); F: 41 ; (39.7 - 42.2)
  **Nabipour et al. (**[@A24723R52]**)**        Bushehr, Genaveh, and Deilam, local study                                                                                            Healthy adults                                                   Random Cluster sampling                          2003 - 2004   2007               ≥ 25                                                                 Both     Both          T: 3,723; M: 1,746; F: 1,977    ATP III                                                                                                                                                                                                                                                                                    T: 52.1 (47.3 - 50.6); M: 54.6 (50.3 - 53.6); F: 49.9 (44.5 - 48.5)
  **Sadrbafghi et al. (**[@A24723R53]**)**      Yazd, local study                                                                                                                    Healthy adults                                                   Random Cluster sampling                          2004          2006               20 - 74        T:49 ± 18; M: 48.9 ± 15.4; F: 49.2 ± 21.4             Both     U             T: 1,110; M: 550; F: 557        ATP III                                                                                                                                                                                                                                                                                    T: 32.1 (29.3 - 34.9); M: 37.8 (33.7 - 42.0); F: 62.2 (57.9 - 66.1)
  **Fakhrzadeh et al. (**[@A24723R54]**)**      Tehran, local study                                                                                                                  Healthy adults                                                   Single-stage cluster sampling                    2003          2006               25 - 64        T: 41.26 ± 12.06                                      Both     U             T: 1,480; M: 571; F: 909        ATP III                                                                                                                                                                                                                                                                                    T: 29.9 (27.6 - 32.2); M: 20.3 (17.08 - 23.85); F: 35.9 (32.74 - 39.07)
  **Azizi et al. (**[@A24723R16]**)**           Tehran, (TLGS, phase 1), local study                                                                                                 Healthy adults                                                   Multistage, stratified random cluster sampling   1999 - 2001   2003               ≥ 20                                                                 Both     U             T: 10,368; M: 4,397; F: 5,971   ATP III                                                                                                                                                                                                                                                                                    T: 33.7 (32.8 - 34.6); M: 24 (22.7 - 25.2); F: 42 (40.7 - 43.2)

The total sample sizes of studies using the criteria of ATP III, IDF, and JIS were 54,043, 23,774, and 1,088, respectively ([Table 2](#tbl35802){ref-type="table"}). For ATP III criteria, the maximum and minimum sample sizes were 12,514 (in Isfahan) and 137 (in Tehran), respectively. Maximum and minimum sample sizes for IDF were 10,368 and 486 (both in Tehran) and for JIS, they were 4,665 and 365 (both in Tehran), respectively. The overall estimation of MetS prevalence was 36.9% (95% CI: 32.7 - 41.2%) according to ATP III, 34.6% (95% CI: 31.7 - 37.6%) for IDF, and 41.5% (95% CI: 29.8 - 53.2%) based on the JIS criteria ([Table 2](#tbl35802){ref-type="table"} and [Figure 2](#fig26341){ref-type="fig"}). The prevalence of MetS measured by JIS was higher than those measured by the ATP III and IDF definitions (41.5% versus 36.9% and 34.6%); however, this difference was not statistically significant. Maximum and minimum prevalence rates of MetS were 60% and 23% based on the ATP III criteria, 40% and 30% for the IDF criteria, and 52% and 31% for the JIS criteria, respectively ([Figure 2](#fig26341){ref-type="fig"}).

###### The Overall Prevalence of Metabolic Syndrome in the Iranian Adult Population According to Different Criteria and Sex Using Random Effect Meta-Analysis of Data From Population-based Studies

  Criteria                               Extracted articles (n)   Sample size (n)   Prevalence (%)   CI 95%
  -------------------------------------- ------------------------ ----------------- ---------------- -------------
  **ATP III**                                                                                        
  Male                                   15                       24,760            27.7             21.8 - 33.6
  Female                                 19                       32,046            43.1             37.9 - 48.4
  Total                                  17                       54,043            36.9             32.7 - 41.2
  **Heterogeneity ATP III (I-square)**                                                               
  Male                                   99.9%                    P \< 0.001                         
  Female                                 99.8%                    P \< 0.001                         
  Total                                  99.8%                    P \< 0.001                         
  **IDF**                                                                                            
  Male                                   6                        9,874             30.7             23.9 - 37.5
  Female                                 6                        12,498            42.0             37.4 - 46.6
  Total                                  7                        23,774            34.6             31.7 - 37.6
  **Heterogeneity IDF (I-square)**                                                                   
  Male                                   99.6%                    P \< 0.001                         
  Female                                 99%                      P \< 0.001                         
  Total                                  98.9%                    P \< 0.001                         
  **JIS**                                                                                            
  Male                                   1                        1,856             45.7             44.6 - 46.8
  Female                                 2                        2,815             37.3             32.4 - 42.2
  Total                                  4                        10,385            41.5             29.8 - 53.2
  **Heterogeneity JIS (I-square)**                                                                   
  Male                                   \-                                                          
  Female                                 99.9%                    P \< 0.001                         
  Total                                  99.8%                    P \< 0.001                         

![Forest Plot of the Prevalence of Metabolic Syndrome in the Iranian Adult Population](ircmj-17-12-24723-i002){#fig26341}

According to the ATP III criteria, the prevalence of MetS was significantly (15.4%) lower in men than in women (27.7% versus 43.1%, respectively). The same trend was obtained for the IDF definition, which found MetS to be 11.3% less prevalent in men than in women (30.7% versus 42.0%, respectively). However, the reverse was true for the JIS definition, which showed a significantly higher (8.4%) prevalence in men than in women (45.7% versus 37.3%, respectively) ([Table 2](#tbl35802){ref-type="table"}, [Figures 3](#fig26342){ref-type="fig"} and [4](#fig26343){ref-type="fig"}).

![Forest Plot of the Prevalence of Metabolic Syndrome in the Iranian Male Adult Population](ircmj-17-12-24723-i003){#fig26342}

![Forest Plot of the Prevalence of Metabolic Syndrome in the Iranian Female Adult Population](ircmj-17-12-24723-i004){#fig26343}

The results of the meta-regression show that the main source of heterogeneity in findings was the mean age of participants. The results show that by each year increase in the mean age of individuals after the age of 18, the prevalence of MetS increased by 0.004% (coefficient: 0.0048792, P = 0.005).

Nine studies reported the prevalence of MetS components according to different criteria ([Table 3](#tbl35803){ref-type="table"}). Among these studies, in six the prevalence of components was calculated in subjects with MetS. Most of the subjects with MetS had three components (54.7% - 95%). The prevalences of four and five components in MetS subjects were 0.6 - 34% and 0 - 11.8%, respectively.

###### Prevalence of Metabolic Syndrome Components in the Iranian Adult POPULATION in Population-Based Studies^[a](#fn38144){ref-type="table-fn"}^

  Reference                                  Location and type of study                                      Study population   Sampling method                                 Study date    Publication date   Age range (years)   Mean age (mean ± SD)                             Sex    Urban/rural   Sample size                    Criteria                         Prevalence of MetS components (%)
  ------------------------------------------ --------------------------------------------------------------- ------------------ ----------------------------------------------- ------------- ------------------ ------------------- ------------------------------------------------ ------ ------------- ------------------------------ -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Tohidi et al. (**[@A24723R44]**)**       Ghazvin, Kermanshah, Golestan, and Hormozgan, multicity study   Healthy adults     Multistage random cluster sampling                            2011               18 - 45                                                              F      U             T: 914                         Modified ATP III                 3 components: 11.4; 4 components: 5.1; 5 components: 1
  **Fakhrzadeh et al. (**[@A24723R54]**)**   Isfahan (cohort study), local study                             Healthy adults     Random stratified sampling                                    2011               43 - 82             56.42 ± 9.52                                     Both   Both          T: 468; M: 236; F: 232         ATP III                          3 components: 55.2; 4 components: 34; 5 components: 10.8
  **Jalali et al. (**[@A24723R46]**)**       Akbar abad Koar Fars near Shiraz, local study                   Healthy adults     Simple random sampling                          2008 (1387)   2009               18 - 90             T: 38.7 ± 14.3; M: 40.5 ± 15.9; F: 37.4 ± 13.7   Both   R             T: 1,402; M: 360; F: 1,042     ATP III; Modified ATP III; IDF   Total, 3 components: 95; 4 components : 0.6; 5 components: 4.5; male, 3 components: 99; 4 components: 0; 5 components:1; female, 3 components: 93.4; 4 components: 0.6; 5 components: 6. Total, 3 components: 66.3; 4 components: 27.1; 5 components: 6.7; male, 3 components: 71.4; 4 components: 26.1; 5 components: 2.5; female, 3 components: 64.1; 4 components: 27.5; 5 components: 8.4. Total, 3 components: 54.7; 4 components: 33.4; 5 components: 11.8; Male, 3 components: 38.4; 4 components: 44.8; 5 components: 16.8; Female, 3 components: 59; 4 components: 30.5; 5 components: 10.5
  **Delavar et al. (**[@A24723R47]**)**      Babol, local study                                              Female adults      Systematic random sampling                                    2009               30 - 50             F: 40.2 ± 0.2                                    F      U             T: 944                         ATP III                          1 component: 30.8; 2 components: 28.9; 3 components: 22.6; 4 components: 7.4; 5 components: 0.8
  **Sharifi et al. (**[@A24723R48]**)**      Zanjan, local study                                             Healthy adults     Stratified, multistage random sampling          2002 - 2003   2009               \> 20                                                                Both   U             T: 2,941; M: 1,396; F: 1,545   Modified ATP III                 3 components: 75.6; 4 components: 24.4; 5 components: 0
  **Nabipour et al. (**[@A24723R52]**)**     Bushehr, Genaveh, and Deilam, local study                       Healthy adults     Random cluster sampling                         2003 - 2004   2007               ≥ 25                                                                 Both   Both          T: 3,723; M: 1,746; F: 1,977   ATP III                          0 components: 4.0; 1 component: 15.1; 2 components: 28.7; 3 components: 30.8; 4 components: 17.7; 5 components: 3.6
  **Sadrbafghi et al. (**[@A24723R53]**)**   Yazd, local study                                               Healthy adults     Random cluster sampling                         2004 (1383)   2006               20 - 74             T: 49 ± 18; M: 48.9 ± 15.4; F: 49.2 ± 21.4       Both   U             T: 1,110; M: 550; F: 557       ATP III                          0 components: 19.2; 1 component: 21.1; 2 components: 27.6; 3 components: 20.8; 4 components: 9; 5 components: 2.3
  **Fakhrzadeh et al. (**[@A24723R54]**)**   Tehran, local study                                             Healthy adults     Single stage cluster sampling                   2003          2006               25 - 64             T: 41.26 ± 12.06                                 Both   U             T: 1,480; M: 571; F: 909       ATP III                          0 component: 12; 1 component: 29; 2 components: 29.1; 3 components: 22.7; 4 components: 7.1; 5 components: 0.2
  **Azizi et al. (**[@A24723R16]**)**        Tehran, (TLGS, phase 1), local study                            Healthy adults     Multistage stratified random cluster sampling   1999 - 2001   2003               ≥ 20                                                                 Both   U             T:10,368; M: 4,397; F: 5,971   ATP III                          Total, 3 components: 58; 4 components: 33; 5 components: 9; Male, 1 component: 29; 2 components: 32; 3 components: 16; 4 components: 7; 5 components: 1; Female, 1 component: 28; 2 components: 23; 3 components: 20; 4 components: 14; 5 components: 4

^a^Abbreviations: F, female; M, male; T, total.

7. Conclusions {#sec139068}
==============

Our findings show that the prevalence of MetS is relatively high in Iran according to all three definitions (ATP III: 36.9%, IDF: 34.6%, and JIS: 41.5%). These observed prevalence rates are noticeably higher than the estimated prevalence around the world, which is between 20% and 25% ([@A24723R7]). The mean prevalence of MetS in Iran was found to be higher than in many other countries (e.g., Portugal \[27.6%\], ([@A24723R55]) Spain \[26.6%\], ([@A24723R56]) France \[25% in males and 15.3% in females\], ([@A24723R57]) and Italy \[22% in males and 18% in females\]) ([@A24723R3]). It was also higher than in the United States of America (22.9%) ([@A24723R58]). The prevalence of MetS in Iran is much closer to that in North Africa (30%), ([@A24723R59]) Asia-China (33.9%), ([@A24723R60]) Turkey (36.6%), ([@A24723R60]) and some Latin American countries such as Colombia (34.8%) ([@A24723R61])and Venezuela (35.3%) ([@A24723R62]). Therefore it can be assumed that some reasons other than urbanization and inactivity have resulted in this relatively high prevalence of MetS in Iran. In a study conducted by Delavari et al., greater waist circumference values and lower HDL cholesterol have also been reported in Iranian communities than in Western populations, which support the idea of an ethnic predisposition of the Iranian community to MetS ([@A24723R14]).

It is noteworthy to acknowledge that comparisons between Iran and other countries must be made with caution. First, because most of these studies were conducted in a small area or a city, they cannot be representative of the entire country. Thus, generalizing the estimated prevalence to a country is a point of concern. Second, it has been shown that MetS is highly age-dependent ([@A24723R63]). This was also found in our study; the prevalence of MetS in the Iranian population increased around 0.004% by each year of age increase after the age of 18. Therefore, even in a study with population-based sampling, comparing countries with different age pyramids might result in different prevalence rates, even with comparable risks of MetS. In recent years, the population of Iran has been growing older, and this might be one of the reasons for such a high prevalence of MetS in this country.

Another finding of this study was the significantly higher prevalence of MetS and its reverse sex distribution according to JIS compared to the other two definitions. According to the ATP III and IDF definitions, MetS prevalence was significantly higher in women (15.4% and 11.3% higher than the prevalence in men, respectively). However, based on the JIS criteria, MetS was 8.4% more prevalent in men, which was also significant. The lack of consensus on MetS definitions and the cutoff points used for its components, especially regarding waist circumference, has resulted in these differences. In the JIS definition, the cut-off point for waist circumference is usually higher than those of ATP III and IDF for women and lower for men, which may have resulted in a higher prevalence of MetS being measured in men according to the JIS definition, and contrary to the ATP III and IDF definitions. These differences influence health policies and clinical practice, in which underestimation or overestimation may result in inappropriate distribution of health services. Barbosa et al. performed a cross-sectional study on 1,439 adults in Brazil and concluded that NCEP-ATP III ([@A24723R64]) underestimated the prevalence of MetS, particularly in men. This study showed that MetS is a public health problem in Iran. It has a high prevalence and it is expected to have an increasing trend in coming years as the mean age of the Iranian population grows. Therefore, by implementing an appropriate screening and treatment system, many metabolic diseases (such as diabetes and cardiovascular disease) that are costly to society can be prevented.

The main limitation of this study is that estimated prevalences were not adjusted based on the size of the target populations. Regarding this point, the results of a cluster analysis method are much more reliable, but cluster sampling is not practical because it is very difficult and expensive to perform. It seems that meta-analysis could be an efficient substitute strategy.

The prevalence of MetS is relatively high in the Iranian adult population. The lack of consensus on MetS definitions has resulted in different reports of its prevalence. However, even considering the lowest prevalence of 34.6%, the prevalence of MetS in Iran is considerably higher than the estimated prevalence around the world (20 - 25%). Therefore, applying an appropriate screening and treatment system for MetS could prevent many chronic diseases that are costly to society.
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